Evidence map›Paper›PMID 40800094›Full record

ArticleTranslational andrology and urology2025

Unveiling SNX10: a key player in bladder cancer progression.

Fan Yang, Kang Qiu, Jianhua Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fan YangDepartment of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kang QiuDepartment of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianhua DengDepartment of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bladder cancer (BC) ranks as the tenth most common cancer globally, posing a substantial public health burden. Its incidence exhibits marked geographic and demographic variations, emphasizing the need for tailored research and therapeutic approaches. Current strategies prioritize inhibiting BC cell proliferation and invasion to improve survival outcomes. In this study, analysis of 408 BC samples revealed sorting nexin 10 ( Methods: To investigate Results: Conclusions: This study identifies

Indexed as

bladder cancer (BC)MYBL2Sorting nexin 10 (SNX10)target therapytumor progression

Identifiers

PMID40800094
PMCPMC12336732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.